short course antiseisure medication in children & adolescent (low risk subgroup) with single calcified brain NCC
Not Applicable
Completed
- Conditions
- Health Condition 1: B699- Cysticercosis, unspecified
- Registration Number
- CTRI/2022/02/040197
- Lead Sponsor
- All India Institute of Medical Science New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 34
Inclusion Criteria
a)Children and adolescents aged 2-18 years with single parenchymal calcified or granular NCC with follow up from viable NCC stage
b)Seizure free on ASM for 6-9 months or12-15 months
C) resolving or calcified NCC @ 6 month CECT
Exclusion Criteria
h/o status epilepticus requiring hospitalization
three or more episodes of seizures after starting ASM
significant perilesional edema ( 2 times the size of calcified focus or any size of perilesional edema with calcified focus >1 cm.
any other brain pathogy ( hippocampal sclerosis, vascular malmormation, old insult sequale)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a)to identify a low-risk group by risk assessment based on clinical, EEG, and MRI brain parameters which has low probability of seizure recurrence, and <br/ ><br>b)to estimate the incidence of staying seizure free after early tapering of ASM in the low-risk group with follow up duration of at least 6 months <br/ ><br>Timepoint: 6 months after stopping ASM
- Secondary Outcome Measures
Name Time Method a)to estimate the association of MRI brain parameters with seizure recurrence in the low-risk group after early tapering of ASM with follow up duration of at least 6 months <br/ ><br>b)to estimate the association of clinical, EEG and MRI brain parameters with seizure recurrence in patients not included in the low-risk group and on ASM therapy during the study period <br/ ><br>Timepoint: follow up duration at least 6 months